Year: 2020
Type: report
Abstract: The ACMD reviewed etizolam and a group of previously uncontrolled benzodiazepines in December 2016, prompted by concerns of the abuse potential of etizolam and its involvement in several deaths across the UK [ACMD, 2016a]. That report recommended that etizolam and 15 other previously uncontrolled benzodiazepines (listed in Annex A) should be controlled under Class C of the Misuse of Drugs Act 1971 (MDA) and placed under Schedule 1 of the Misuse of Drugs Regulations 2001 (MDR) [ACMD, 2016b]. These controls came into force in May 2017. 1.2. The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) collates information about novel psychoactive substances identified from participating countries in seizures, test purchasing and forensic testing, and records this information on the European Database on New Drugs (EDND). Since the publication of the ACMD (2016) report there have been notifications of 9 benzodiazepines detected in seizures across Europe and reported to the EMCDDA, and the ACMD have identified a further 4 benzodiazepines listed on the EDND. These 13 benzodiazepines are not currently classified under the MDA. Although some of these compounds were originally developed as medicines in the 1960s and 1970s and some are currently licensed medicines in other countries, they are considered to be novel psychoactive substances in the context of drug misuse. 1.3. This report examines the UK prevalence and available evidence of harm of these 13 benzodiazepines and makes recommendations about inclusion of some of these substances in the MDA and MDR. For the purposes of this report, the term novel benzodiazepines refers to this list of 13 substances.
Authors: Campbell, Anne, VARIOUS AUTHORS, ACMD
Language: English
Subfield: Toxicology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7011807613
